Printed From:

Consistent Improvements in TNF-IR and MTX-IR Patients

Robust efficacy in patients with prior history of inadequate response1

Robust efficacy in patients with prior history of inadequate response1

With KEVZARA 150 mg + DMARD (TARGET), 56% of patients achieved ACR20 response, 37% achieved ACR50 response, and 20%|| achieved ACR70 response week 24 (n=181)

With KEVZARA 150 mg + MTX (MOBILITY), 58% of patients achieved ACR20 response, 37% achieved ACR50 response, and 20% achieved ACR70 response at week 24 (n=400)

*After week 12 in TARGET and week 16 in MOBILITY, patients with an inadequate response could have been treated with open-label KEVZARA 200 mg every 2 weeks P<0.0001; P<0.01; §DMARDs in TARGET include MTX, sulfasalazine, leflunomide, and/or hydroxychloroquine; ||P<0.001.

Reduction in Signs and Symptoms Were Observed Across all ACR Components (week 24)4
REDUCTION IN PAIN

REDUCTION IN PAIN

from baseline with
KEVZARA 200 mg + DMARD

compared to 39% reduction with
placebo + DMARD

REDUCTION IN TENDER AND SWOLLEN JOINTS

REDUCTION IN TENDER AND SWOLLEN JOINTS

from baseline with
KEVZARA 200 mg + DMARD

  • A 70% reduction in tender joints
    compared to 59% reduction with
    placebo + DMARD

  • A 73% reduction in swollen joints
    compared to 63% reduction with
    placebo + DMARD

REDUCTION IN MEDIAN CRP

REDUCTION IN MEDIAN CRP

levels from baseline with
KEVZARA 200 mg + DMARD

compared to 25% reduction with
placebo + DMARD

  • With KEVZARA 150 mg + DMARD, reduction from baseline was 69% in tender and 72% in swollen joints, 49% in pain, and 87% in median CRP4

As early as 2 weeks after the first dose, KEVZARA normalized CRP levels (<10 mg/L) in patients with elevated CRP1,5

Sustained Efficacy in ACR50 and ACR70 (Week 52)1,3
ACR50 RESPONSE

ACR50 RESPONSE

with KEVZARA 200 mg + MTX
(P<0.0001) 18% response with
placebo + MTX

ACR70 RESPONSE

ACR70 RESPONSE

with KEVZARA 200 mg + MTX
(P<0.0001) 9% response with
placebo + MTX

Rapid and Sustained ACR Response in Patients

Inhibit Progression of Joint Damage

Help control radiographic progression in your patients1

KEVZARA 200 mg + MTX provided an absolute difference of 2.52 units (CI: -3.38, -1.66) in mean ΔTSS relative to placebo + MTX

  • 68%* inhibition of joint damage progression with KEVZARA 150 mg + MTX at week 52 relative to placebo + MTX1

    • KEVZARA 150 mg + MTX provided an absolute difference of 1.88 units in mean mTSS relative to placebo + MTX

KEVZARA 200 mg + MTX significantly inhibited the progression of joint damage1

Week 52 analysis employs linear extrapolation method to impute missing or postrescue data.
*Based on post hoc comparisons of mean change in mTSS per treatment group.
CI=confidence interval.

Study Design

References: 1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc; 2017. 2. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277-290. 3. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424-1437. 4. Data on file, Sanofi/Regeneron. Integrated summary. April 1, 2017. 5. Center for Devices and Radiological Health. Guidance for industry and FDA staff: review criteria for assessment of c-reactive protein (CRP), high sensitivity c-reactive protein (hsCRP) and cardiac c-reactive protein (cCRP) assays. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm071017.pdf. Accessed October 18, 2017.